The Instituto Português de Oncologia Francisco Gentil, also known as the Instituto Português de Oncologia, Portuguese for Portuguese Oncology Institute, is a state-run cancer hospital and research organization in Portugal. The I.P.O. has autonomous regional branches in Lisbon, Porto and Coimbra.

During the past decade, IPO Lisboa conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 1 clinical trials were completed, i.e. on average, 14.3% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "IPO Lisboa" #1 sponsor was "SOLTI Breast Cancer Research Group" with 2 trials, followed by "Bayer" with 1 trials sponsored, "Fadoi Foundation, Italy" with 1 trials sponsored, "Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III" with 1 trials sponsored and "Genmab" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "IPO Lisboa" #1 collaborator was "Alliance Foundation Trials, LLC." with 1 trials as a collaborator, "European Commission" with 1 trials as a collaborator, "Novartis" with 1 trials as a collaborator and "University of Perugia, Italy" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "IPO Lisboa" are "Anthracycline-induced Cardiac Toxicity" (1 trials), "Breast Cancer" (1 trials), "Cancer" (1 trials), "Head and Neck Cancer" (1 trials) and "Metastatic Breast Cancer" (1 trials). Many other conditions were trialed in "IPO Lisboa" in a lesser frequency.

Most popular intervention types in "IPO Lisboa" are "Drug" (6 trials), "Device" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Apalutamide" (1 trials), "Apixaban" (1 trials), "Dalteparin" (1 trials), "Darolutamide (Nubeqa, BAY1841788)" (1 trials) and "LHRHa" (1 trials). Other intervention names were less common.

The vast majority of trials in "IPO Lisboa" are 6 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "IPO Lisboa". undefined are not yet recruiting, 4 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in IPO Lisboa, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in IPO Lisboa, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".